| Code | CSB-RA007690MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SRF-617, designed for research targeting ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is an ectoenzyme that catalyzes the hydrolysis of extracellular ATP and ADP to AMP, playing a critical role in purinergic signaling and immune regulation. By depleting extracellular ATP, ENTPD1 helps modulate inflammatory responses and creates an immunosuppressive microenvironment. This enzyme is highly expressed on regulatory T cells, tumor-infiltrating lymphocytes, and various cancer cells, where it contributes to immune evasion by suppressing effector T cell function and promoting tumor progression. Elevated ENTPD1 expression has been associated with multiple malignancies, including colorectal cancer, pancreatic cancer, and hematologic malignancies.
SRF-617 represents a therapeutic antibody candidate developed to block ENTPD1 enzymatic activity, aiming to restore anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating ENTPD1-mediated immune suppression mechanisms, evaluating therapeutic strategies targeting the purinergic pathway, and studying tumor immunology in preclinical models.
There are currently no reviews for this product.